These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21561048)

  • 21. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost effectiveness of preventing cardiovascular diseases.
    Grover SA
    Can J Cardiol; 1999 Dec; 15 Suppl G():114G-6G. PubMed ID: 10692671
    [No Abstract]   [Full Text] [Related]  

  • 23. Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs.
    Daviglus ML; Liu K; Greenland P; Dyer AR; Garside DB; Manheim L; Lowe LP; Rodin M; Lubitz J; Stamler J
    N Engl J Med; 1998 Oct; 339(16):1122-9. PubMed ID: 9770560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An ounce of prevention.
    Fuster V
    Nat Rev Cardiol; 2009 Sep; 6(9):553-4. PubMed ID: 19696772
    [No Abstract]   [Full Text] [Related]  

  • 26. Strategic and cost effective role for preventive cardiology.
    Dunn PJ; Ryan MJ; Hiebert M
    J Cardiovasc Manag; 1998; 9(6):13-20. PubMed ID: 10350995
    [No Abstract]   [Full Text] [Related]  

  • 27. Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
    Fodor JG; Whitmore B; Leenen F; Larochelle P
    CMAJ; 1999 May; 160(9 Suppl):S29-34. PubMed ID: 10333851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glaucoma care cost-effectiveness.
    Hoskins HD
    Ophthalmology; 2009 May; 116(5):1016. PubMed ID: 19410965
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-utility of a cardiovascular prevention program in highly educated adults: intermediate results of a randomized controlled trial.
    Jacobs N; Evers S; Ament A; Claes N
    Int J Technol Assess Health Care; 2010 Jan; 26(1):11-9. PubMed ID: 20059776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.
    Annemans L; Lamotte M; Clarys P; Van den Abeele E
    Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):815-24. PubMed ID: 18043305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From cardiovascular disease to cardiovascular health: a quiet revolution?
    Labarthe DR
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):e86-92. PubMed ID: 23170007
    [No Abstract]   [Full Text] [Related]  

  • 34. [Sodium intake and hypertension].
    Imbs JL; Welsch M; Grima M; Stephan D
    Arch Mal Coeur Vaiss; 2000 Nov; 93(11 Suppl):1417-22. PubMed ID: 11190290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hypertension initiative of South Carolina. Promoting cardiovascular health through better blood pressure control.
    Giese M; Lackland DT; Egan BM
    J S C Med Assoc; 2001 Feb; 97(2):57-62. PubMed ID: 11235117
    [No Abstract]   [Full Text] [Related]  

  • 37. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium intake and cardiovascular disease.
    Morrison AC; Ness RB
    Annu Rev Public Health; 2011; 32():71-90. PubMed ID: 21219163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Money for health: the equivalent variation of cardiovascular diseases.
    Groot W; Van Den Brink HM; Plug E
    Health Econ; 2004 Sep; 13(9):859-72. PubMed ID: 15362178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.